New and Emerging Targeted Therapies for Cystic Fibrosis

Overview

Journal BMJ

Specialty General Medicine

Date 2016 Apr 1

PMID 27030675

Citations 59

Authors

Bradley S Quon

Steven M Rowe

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis (CF) is a monogenic autosomal recessive disorder that affects about 70,000 people worldwide. The clinical manifestations of the disease are caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The discovery of the CFTR gene in 1989 has led to a sophisticated understanding of how thousands of mutations in the CFTR gene affect the structure and function of the CFTR protein. Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations. Furthermore, there is considerable optimism about the prospect of gene replacement or editing therapies to correct all mutations in cystic fibrosis. The recent approvals of ivacaftor and lumacaftor represent the genesis of a new era of precision medicine in the treatment of this condition. These drugs are having a positive impact on the lives of people with cystic fibrosis and are potentially disease modifying. This review provides an update on advances in our understanding of the structure and function of the CFTR, with a focus on state of the art targeted drugs that are in development.

Citing Articles

Aqueous extracts of and as promising sources of antibiofilm compounds against mucoid and small colony variants of and .

Silva E, Ferreira-Santos P, Teixeira J, Pereira M, Rocha C, Sousa A Biofilm. 2025; 9:100250.

PMID: 39877233 PMC: 11772965. DOI: 10.1016/j.bioflm.2024.100250.

Advancing the Battle against Cystic Fibrosis: Stem Cell and Gene Therapy Insights.

Shah D, Chorawala M, Pandya A, Kothari N, Prajapati B, Parekh P Curr Med Sci. 2024; 44(6):1155-1174.

PMID: 39676146 DOI: 10.1007/s11596-024-2936-5.

FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium.

Easter M, Hirsch M, Harris E, Howze 4th P, Matthews E, Jones L JCI Insight. 2024; 9(15).

PMID: 38916962 PMC: 11383597. DOI: 10.1172/jci.insight.174888.

The burden of cystic fibrosis in North Africa.

El Makhzen N, Daimi H, Bouguenouch L, Abriel H Front Genet. 2024; 14:1295008.

PMID: 38269366 PMC: 10806102. DOI: 10.3389/fgene.2023.1295008.

Precision Medicine: Disease Subtyping and Tailored Treatment.

Wang R, Wang Z Cancers (Basel). 2023; 15(15).

PMID: 37568653 PMC: 10417651. DOI: 10.3390/cancers15153837.

References

Hoegger M, Fischer A, McMenimen J, Ostedgaard L, Tucker A, Awadalla M . Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science. 2014; 345(6198):818-22. PMC: 4346163. DOI: 10.1126/science.1255825. View

Garcia M, Yang N, Quinton P . Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009; 119(9):2613-22. PMC: 2735925. DOI: 10.1172/JCI38662. View

Barry P, Jones A, Webb A, Horsley A . Sweat chloride is not a useful marker of clinical response to Ivacaftor. Thorax. 2013; 69(6):586-7. DOI: 10.1136/thoraxjnl-2013-204532. View

Moss R, Rodman D, Terry Spencer L, Aitken M, Zeitlin P, Waltz D . Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest. 2004; 125(2):509-21. DOI: 10.1378/chest.125.2.509. View

Davies J, Wainwright C, Canny G, Chilvers M, Howenstine M, Munck A . Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013; 187(11):1219-25. PMC: 3734608. DOI: 10.1164/rccm.201301-0153OC. View

Lubamba B, Lecourt H, Lebacq J, Lebecque P, de Jonge H, Wallemacq P . Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med. 2007; 177(5):506-15. DOI: 10.1164/rccm.200703-344OC. View

Boyle M, De Boeck K . A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2014; 1(2):158-63. DOI: 10.1016/S2213-2600(12)70057-7. View

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

Clancy J, Bebok Z, Ruiz F, King C, Jones J, Walker L . Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001; 163(7):1683-92. DOI: 10.1164/ajrccm.163.7.2004001. View

10.

Denning G, Ostedgaard L, Welsh M . Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol. 1992; 118(3):551-9. PMC: 2289545. DOI: 10.1083/jcb.118.3.551. View

11.

Hyde S, Southern K, Gileadi U, Fitzjohn E, Mofford K, Waddell B . Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 2000; 7(13):1156-65. DOI: 10.1038/sj.gt.3301212. View

12.

Zielenski J, Tsui L . Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995; 29:777-807. DOI: 10.1146/annurev.ge.29.120195.004021. View

13.

McCoy K, Quittner A, Oermann C, Gibson R, Retsch-Bogart G, Montgomery A . Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178(9):921-8. PMC: 2577727. DOI: 10.1164/rccm.200712-1804OC. View

14.

Howard M, Frizzell R, Bedwell D . Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996; 2(4):467-9. DOI: 10.1038/nm0496-467. View

15.

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

16.

Boyle M, Bell S, Konstan M, McColley S, Rowe S, Rietschel E . A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014; 2(7):527-38. DOI: 10.1016/S2213-2600(14)70132-8. View

17.

Hoare S, McEvoy S, McCarthy C, Kilcoyne A, Brady D, Gibney B . Ivacaftor imaging response in cystic fibrosis. Am J Respir Crit Care Med. 2014; 189(4):484. DOI: 10.1164/rccm.201308-1433IM. View

18.

Hayes Jr D, McCoy K, Sheikh S . Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Respir Crit Care Med. 2014; 190(4):468. DOI: 10.1164/rccm.201403-0595IM. View

19.

McKone E, Borowitz D, Drevinek P, Griese M, Konstan M, Wainwright C . Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014; 2(11):902-910. DOI: 10.1016/S2213-2600(14)70218-8. View

20.

Hayes Jr D, McCoy K, Sheikh S . Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014; 190(5):590-1. DOI: 10.1164/rccm.201405-0882LE. View